Logo image of LUNG

PULMONX CORP (LUNG) Stock Fundamental Analysis

USA - NASDAQ:LUNG - US7458481014 - Common Stock

1.84 USD
+0.15 (+8.88%)
Last: 9/22/2025, 8:41:37 PM
1.78 USD
-0.06 (-3.26%)
After Hours: 9/22/2025, 8:41:37 PM
Fundamental Rating

3

Overall LUNG gets a fundamental rating of 3 out of 10. We evaluated LUNG against 190 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of LUNG have multiple concerns. LUNG is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year LUNG has reported negative net income.
LUNG had a negative operating cash flow in the past year.
In the past 5 years LUNG always reported negative net income.
In the past 5 years LUNG always reported negative operating cash flow.
LUNG Yearly Net Income VS EBIT VS OCF VS FCFLUNG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

LUNG has a Return On Assets of -38.69%. This is in the lower half of the industry: LUNG underperforms 61.58% of its industry peers.
The Return On Equity of LUNG (-82.41%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -38.69%
ROE -82.41%
ROIC N/A
ROA(3y)-33.09%
ROA(5y)-26.44%
ROE(3y)-51.8%
ROE(5y)-38.97%
ROIC(3y)N/A
ROIC(5y)N/A
LUNG Yearly ROA, ROE, ROICLUNG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

1.3 Margins

LUNG has a better Gross Margin (73.07%) than 83.68% of its industry peers.
In the last couple of years the Gross Margin of LUNG has remained more or less at the same level.
LUNG does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 73.07%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.19%
GM growth 5Y1.48%
LUNG Yearly Profit, Operating, Gross MarginsLUNG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

More info and screens

3

2. Health

2.1 Basic Checks

LUNG does not have a ROIC to compare to the WACC, probably because it is not profitable.
LUNG has more shares outstanding than it did 1 year ago.
The number of shares outstanding for LUNG has been increased compared to 5 years ago.
LUNG has a worse debt/assets ratio than last year.
LUNG Yearly Shares OutstandingLUNG Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
LUNG Yearly Total Debt VS Total AssetsLUNG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -4.02, we must say that LUNG is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -4.02, LUNG is not doing good in the industry: 66.84% of the companies in the same industry are doing better.
A Debt/Equity ratio of 0.54 indicates that LUNG is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.54, LUNG is doing worse than 64.21% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.54
Debt/FCF N/A
Altman-Z -4.02
ROIC/WACCN/A
WACC8.32%
LUNG Yearly LT Debt VS Equity VS FCFLUNG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M

2.3 Liquidity

LUNG has a Current Ratio of 5.35. This indicates that LUNG is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of LUNG (5.35) is better than 78.42% of its industry peers.
LUNG has a Quick Ratio of 4.63. This indicates that LUNG is financially healthy and has no problem in meeting its short term obligations.
LUNG has a better Quick ratio (4.63) than 78.95% of its industry peers.
Industry RankSector Rank
Current Ratio 5.35
Quick Ratio 4.63
LUNG Yearly Current Assets VS Current LiabilitesLUNG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 2.05% over the past year.
Looking at the last year, LUNG shows a quite strong growth in Revenue. The Revenue has grown by 18.23% in the last year.
LUNG shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 20.78% yearly.
EPS 1Y (TTM)2.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8.57%
Revenue 1Y (TTM)18.23%
Revenue growth 3Y20.06%
Revenue growth 5Y20.78%
Sales Q2Q%14.8%

3.2 Future

LUNG is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 28.67% yearly.
Based on estimates for the next years, LUNG will show a very strong growth in Revenue. The Revenue will grow by 31.30% on average per year.
EPS Next Y-12.35%
EPS Next 2Y-0.13%
EPS Next 3Y7.39%
EPS Next 5Y28.67%
Revenue Next Year10.08%
Revenue Next 2Y12.38%
Revenue Next 3Y15.5%
Revenue Next 5Y31.3%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
LUNG Yearly Revenue VS EstimatesLUNG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
LUNG Yearly EPS VS EstimatesLUNG Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 -4 6 8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LUNG. In the last year negative earnings were reported.
Also next year LUNG is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LUNG Price Earnings VS Forward Price EarningsLUNG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LUNG Per share dataLUNG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-0.13%
EPS Next 3Y7.39%

More info and screens

0

5. Dividend

5.1 Amount

LUNG does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PULMONX CORP

NASDAQ:LUNG (9/22/2025, 8:41:37 PM)

After market: 1.78 -0.06 (-3.26%)

1.84

+0.15 (+8.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)07-30 2025-07-30/amc
Earnings (Next)10-28 2025-10-28/amc
Inst Owners91.98%
Inst Owner Change-1.43%
Ins Owners4.21%
Ins Owner Change4.25%
Market Cap74.98M
Analysts80
Price Target6.89 (274.46%)
Short Float %4.21%
Short Ratio2.31
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)2.76%
Min EPS beat(2)0.21%
Max EPS beat(2)5.3%
EPS beat(4)4
Avg EPS beat(4)13.63%
Min EPS beat(4)0.21%
Max EPS beat(4)27.7%
EPS beat(8)8
Avg EPS beat(8)15.16%
EPS beat(12)12
Avg EPS beat(12)12.31%
EPS beat(16)15
Avg EPS beat(16)10.59%
Revenue beat(2)1
Avg Revenue beat(2)-0.02%
Min Revenue beat(2)-0.33%
Max Revenue beat(2)0.28%
Revenue beat(4)2
Avg Revenue beat(4)0.75%
Min Revenue beat(4)-1.48%
Max Revenue beat(4)4.53%
Revenue beat(8)6
Avg Revenue beat(8)2.08%
Revenue beat(12)9
Avg Revenue beat(12)2.12%
Revenue beat(16)10
Avg Revenue beat(16)2.02%
PT rev (1m)0%
PT rev (3m)-39.69%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-7.05%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.7%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-12.56%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-6.54%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.83
P/FCF N/A
P/OCF N/A
P/B 1.09
P/tB 1.12
EV/EBITDA N/A
EPS(TTM)-1.43
EYN/A
EPS(NY)-1.4
Fwd EYN/A
FCF(TTM)-0.78
FCFYN/A
OCF(TTM)-0.76
OCFYN/A
SpS2.22
BVpS1.7
TBVpS1.64
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -38.69%
ROE -82.41%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 73.07%
FCFM N/A
ROA(3y)-33.09%
ROA(5y)-26.44%
ROE(3y)-51.8%
ROE(5y)-38.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.19%
GM growth 5Y1.48%
F-Score2
Asset Turnover0.62
Health
Industry RankSector Rank
Debt/Equity 0.54
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 70.33%
Cap/Sales 0.97%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.35
Quick Ratio 4.63
Altman-Z -4.02
F-Score2
WACC8.32%
ROIC/WACCN/A
Cap/Depr(3y)78.82%
Cap/Depr(5y)169.58%
Cap/Sales(3y)1.79%
Cap/Sales(5y)3.14%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)2.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8.57%
EPS Next Y-12.35%
EPS Next 2Y-0.13%
EPS Next 3Y7.39%
EPS Next 5Y28.67%
Revenue 1Y (TTM)18.23%
Revenue growth 3Y20.06%
Revenue growth 5Y20.78%
Sales Q2Q%14.8%
Revenue Next Year10.08%
Revenue Next 2Y12.38%
Revenue Next 3Y15.5%
Revenue Next 5Y31.3%
EBIT growth 1Y1.12%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year38.63%
EBIT Next 3Y18.96%
EBIT Next 5Y8.94%
FCF growth 1Y23.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y24.2%
OCF growth 3YN/A
OCF growth 5YN/A